Trials / Terminated
TerminatedNCT00354562
A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-751 | 200mg ABT-751 daily for 14 days every 21 days |
| DRUG | Placebo | Placebo daily for 14 days every 21 days |
| DRUG | Docetaxel | Standard Docetaxel every 21 days |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2008-02-01
- First posted
- 2006-07-20
- Last updated
- 2011-01-07
Locations
32 sites across 4 countries: United States, Canada, Ireland, United Kingdom
Source: ClinicalTrials.gov record NCT00354562. Inclusion in this directory is not an endorsement.